When does Yervoy’s patent expire, and what does that mean for sales?
Yervoy (ipilimumab) is protected by a set of patents (drug substance, formulation, and related inventions) with different expiration dates rather than a single “patent date.” Because of that, the impact on sales is usually gradual: earlier-expiring rights can enable more competitive entry options (like biosimilar development), while later-expiring rights can delay actual market competition.
Once relevant exclusivity and patents expire, manufacturers can seek approval for competing versions, which typically reduces Yervoy’s pricing power and share as payers shift to lower-cost alternatives.
Will biosimilars directly cut Yervoy revenue after patent expiry?
Potentially, yes, but the size and timing of the revenue hit depend on what kind of competition enters immediately after expiry:
- If biosimilars launch promptly in major markets, payers often move quickly to reduce costs, and sales can fall faster than expected.
- If entry is delayed (for example, due to litigation, patent “evergreening” arguments, or manufacturing/approval timelines), Yervoy can retain stronger commercial protection for longer.
The key mechanism is substitution. Even when a competitor is approved, uptake depends on physician and payer confidence, formulary position, and contracting.
How much of Yervoy’s sales is driven by competition exposure?
Yervoy’s sales impact after patent expiry will also depend on the competitive landscape at that time, especially because many oncology immunotherapy regimens increasingly rely on PD-1/PD-L1–based combinations. That means:
- If Yervoy’s clinical place in therapy is already shrinking due to stronger standard-of-care alternatives, patent expiry may cause less incremental damage than a scenario where Yervoy is still expanding.
- If Yervoy remains central to combination protocols when biosimilars arrive, price pressure could translate more directly into revenue declines.
What delays the market impact even after a patent expires?
Patent expiry does not always translate into immediate biosimilar sales because of litigation and regulatory sequencing:
- Patent disputes can delay launch even when a patent expiration date is reached or close.
- If additional patents are still in force (different claims, different jurisdictions, or different product/process aspects), competitors may still be blocked from marketing until those issues are resolved.
So the sales impact often shows up in steps, not in a single sudden drop.
Do payers switch immediately, and how does that change the revenue decline pattern?
Payer behavior is often the fastest driver of the sales curve after exclusivity ends. When biosimilars are available, payers may:
- Require prior authorization or tighter criteria for the originator.
- Prefer the lower-priced option at the same administration setting.
- Use contracting strategies that narrow the net price difference.
That tends to create a relatively front-loaded decline in originator sales after launch, followed by stabilization as competition expands or consolidates.
What happens to Yervoy’s price after biosimilar entry?
Even before biosimilars capture large volume, the threat typically pushes originators to defend net pricing through discounts and managed-care contracting. After biosimilar entry:
- Average selling price often declines as net prices compress.
- Revenues can fall even if total treated patients remain steady, because fewer originator units are sold and unit prices drop.
Could Yervoy regain traction or offset losses post-expiry?
Some factors can soften the impact:
- New indications or line expansions that increase total addressable demand can offset share loss.
- Combination regimen changes that still require ipilimumab can maintain baseline demand.
- Manufacturing scale and supply continuity can influence how quickly competitors take meaningful share.
However, whether these offsets are enough depends on how quickly biosimilars are approved and adopted and how competitive the therapeutic landscape is at launch.
Key uncertainties that determine the actual sales impact
The exact magnitude and timing of Yervoy sales changes after patent expiration will depend on:
- The specific expiration dates for the patents that block biosimilar marketing (not just the earliest expiring one).
- Whether biosimilars launch on day one after those barriers clear.
- Uptake speed by payers and clinicians once alternative products are available.
- Ongoing market headwinds from evolving immunotherapy standards of care.
Sources
I don’t have the specific Yervoy patent expiration date(s) or a cited list of the patents/exclusivities relevant to biosimilar entry in the information provided here, so I can’t state exact timelines or quantify expected sales impacts without additional details (e.g., which country/market and which patent set you mean).